US Stock MarketDetailed Quotes

TNYA Tenaya Therapeutics

Watchlist

3.650
-0.020-0.54%

Trading Jul 23 09:30 ET

286.59MMarket Cap-2212P/E (TTM)

Tenaya Therapeutics Stock Forum

Jaguar8

May 2 16:08

$Tenaya Therapeutics(TNYA.US)$
NEWS
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics is demonstrating continuous innovation in core competencies at the ASGCT 27th Annual Meeting, showcasing its capabilities in genetic medicines for heart disease.
The company's pipeline includes two clinical-stage gene therapies for cardiomyopathies and research on ge...

Trytosaveabit

Mar 28 06:15

Just a bit of information

$Tenaya Therapeutics(TNYA.US)$ The company’s lead product, TN-201, represents a significant advancement in treating genetic hypertrophic cardiomyopathy and is making headway in clinical trials. The anticipation of initial data from these trials in the second half of 2024 is seen as a pivotal moment that could substantially influence the company’s stock valuation.
Furthermore, Tenaya’s second gene therapy product, TN-401, is targeting the treatment of arrhythmogenic right...

Trytosaveabit

Mar 18 07:44

Very cool! Watching

$Tenaya Therapeutics(TNYA.US)$ Tenaya Therapeutics Publishes TN-401 Gene Therapy Preclinical Data In Nature Communications Medicine
Moomoo 24/7· 9 mins ago
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease
Tenaya Anticipates Dosing First ...

LukeM

Jan 22 08:04

$Tenaya Therapeutics(TNYA.US)$ might run today

Moomoo AI

Dec 23, 2023 06:54

Tenaya Therapeutics' finances are precarious with significant cash burn relative to its market cap. Despite decreased cash burn, the absence of revenue and huge spending amplify the risk profile. The company's abilities to secure more funding are in doubt.

We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully

Trytosaveabit

Oct 26, 2023 09:53

A bit more!

$Tenaya Therapeutics(TNYA.US)$ Joseph Pantginis has given a Buy rating to Tenaya Therapeutics based on a number of factors. First and foremost, Pantginis highlights the FDA’s approval of Tenaya’s IND application for TN-401, an AAV9-based gene therapy aimed at treating arrhythmogenic right ventricular cardiomyopathy (ARVC). The clearance by the FDA to initiate clinical testing is seen as a significant step forward. Additionally, Tenaya’s plans to commence the RIDGE-1 Phase 1b trial, wh...